NeoGenomics, Inc. Common Stock (NEO) Stock
NASDAQ · NEO
19.24
Fundamentals
Market cap
$2.48B
Price / Earnings ratio
-48.4x
Price / Sales ratio
3.3x
Price / Book ratio
3.2x
Return on assets
-7.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeutralNEOSeptember 21, 2026
MarketBeatNeutral
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NEO

Business Wire
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeutralNEOSeptember 1, 2026
Business WireNeutral
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEO

Stocktwits
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
NeutralNEOAugust 27, 2026
StocktwitsNeutral
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
NEO

Business Wire
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeutralNEOAugust 26, 2026
Business WireNeutral
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NEO
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
873M576M288M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
2B1B538M0
Revenue to Profit
2025$727.3M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-108.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeutralNEOSeptember 21, 2026
MarketBeatNeutral
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NEO

Business Wire
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeutralNEOSeptember 1, 2026
Business WireNeutral
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEO

Stocktwits
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
NeutralNEOAugust 27, 2026
StocktwitsNeutral
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
NEO

Business Wire
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeutralNEOAugust 26, 2026
Business WireNeutral
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NEO

MarketBeat
Neo Performance Materials Q2 Earnings Call Highlights
NeutralNEOAugust 12, 2026
MarketBeatNeutral
Neo Performance Materials Q2 Earnings Call Highlights
NEO

Zacks Investment Research
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeutralNEOAugust 4, 2026
Zacks Investment ResearchNeutral
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NEO

MarketBeat
NeoGenomics Q2 Earnings Call Highlights
NeutralNEOJuly 28, 2026
MarketBeatNeutral
NeoGenomics Q2 Earnings Call Highlights
NEO

Business Wire
NeoGenomics Reports Second Quarter 2026 Results
NeutralNEOJuly 28, 2026
Business WireNeutral
NeoGenomics Reports Second Quarter 2026 Results
NEO

Business Wire
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeutralNEOJuly 20, 2026
Business WireNeutral
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NEO

Business Wire
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeutralNEOJuly 9, 2026
Business WireNeutral
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NEO
About NeoGenomics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryDiagnostics & Research
Employees2,500
CEOMr. Anthony P. Zook
IPO DateNov 2, 1999
HeadquartersFort Myers, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony P. Zook | CEO & Director | 1961 |
| Mr. Warren Stone | President & COO | 1973 |
| Ms. Elizabeth A. Floegel | Chief Digital & Information Officer | 1976 |
| Mr. Abhishek Jain | Executive VP & CFO | 1976 |
| Mr. Gregory D. Aunan | Senior VP & Chief Accounting Officer | 1969 |
| Mr. Andrew Frederick Brackmann C.F.A. | Vice President of Investor Relations | — |
| Mr. Clarence Cooper Esq. | Vice President of Compliance & Privacy | — |
| Dr. Andrew A. Lukowiak Ph.D. | Chief Innovation Officer | 1972 |
| Priya Vedaraman | Senior Vice President of Finance | — |
| Ms. Kristi McKeown | Chief Commercial Officer | — |
Fundamentals
Valuation
Market cap$2.48B
Price-to-sales ratio3.28
Price-to-book value3.20
Price-earnings ratio-48.40
Return on Equity-12.00%
Return on Sales-13.00%
Return on Assets-7.00%
PEG ratio2.09
Earnings Per Share
Earnings Per Share$-0.39
Income Statement
Average volume2,065,422
EBITDA$-26.06M
1 year high (52w)$20.05
1 year low (52w)$7.07
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$17.50
Est return
8.04%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.2 | -5.1 | -27.2 | +4.1 | ||||||||
| 2022 | -36.1 | -7.3 | -42.3 | -23.7 | -13.6 | +1.2 | +20.9 | -0.8 | -14.5 | -12.6 | +46.5 | -17.3 |
| 2023 | +30.7 | +34.8 | +5.0 | -13.4 | +16.7 | -9.0 | +9.8 | -14.3 | -18.9 | +17.8 | +32.0 | -14.8 |
| 2024 | -6.9 | +5.4 | -1.6 | -9.6 | -1.8 | +2.6 | +27.3 | -5.6 | -7.1 | -1.6 | +26.6 | -8.4 |
| 2025 | -13.3 | -28.0 | -0.9 | -31.6 | +0.3 | +2.0 | -34.7 | +70.2 | -12.4 | +12.0 | +23.7 | -2.2 |
| 2026 | +2.6 | -20.1 | -21.9 | +19.5 | +11.4 | +39.8 | +2.1 | +13.1 | +10.8 |



